The Binding Site Discusses the Suspicion, Investigation and Early Management in Multiple Myeloma in Educational Webinar

Share Article

Through this webinar, which LabRoots will host January 9, participants will be able to more fully and appropriately investigate the presence of a monoclonal protein.

Julie Côté MD, FRCPC

Multiple Myeloma is a hematological tumor of plasma cells in the bone marrow which can appear insidiously. This disease may also be associated with several complications which stresses the importance of an early diagnosis. This educative webinar aims to inform and raise awareness among primary care physicians, general practitioners and internists, about the clinical picture, investigation and rapid care management of Multiple Myeloma patients.

Participants of this webinar, which is sponsored by the Binding Site, will learn to recognize clinical symptoms and signs of Multiple Myeloma. They will gain a better understanding of the importance of rapid care management of Multiple Myeloma patients.

The speaker for this event will be Dr. Julie Côté from the University Hospital Center of Quebec. Côté received her doctorate in medicine at Laval University in Quebec City. She later completed her postdoctoral clinical training in plasma cell dyscrasias at the Princess Margaret Cancer Center in Toronto. She is now part of the medical team of the University Hospital Center of Quebec. She is also a member of Myeloma Canada and the Myeloma Canada Research Network.

LabRoots will host the webinar in French, with English subtitles, on January 9, 2018. The webinar will begin at 9:00 a.m. PST, 6:00 p.m. CET and will be available on demand following the live event. To learn more about this event, discover the continuing education credits that will be offered, or to register for free, click here.

About Binding Site
Binding Site is committed to improving patient lives worldwide through education, collaboration and innovation. The company focuses on research, development, manufacture and distribution of innovative immunodiagnostic systems and assays for the global laboratory market. By utilizing its specialized expertize in antibody specificity technology, Binding Site has developed a broad menu of special protein assays, including the Freelite® test, the only FDA cleared and guideline-recommended serum free light chain assay on the market. Binding Site gives clinicians and laboratory staff the tools to significantly improve diagnosis and management of those patients with specific cancers and immune disorders.

For more information about Binding Site, please visit http://www.thebindingsite.com.

About LabRoots
LabRoots is the leading scientific social networking website, which provides daily scientific trending news, as well as produces educational virtual events and webinars, on the latest discoveries and advancements in science. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Karen Sorenson
LabRoots, Inc.
+1 (619) 861-0590
Email >
Visit website